Traditional brain imaging modalities include magnetic resonance imaging (MRI) and computed tomography (CT) scans, as well as newer emergent imaging technologies are positron emission tomography (PET) and PET-MRI or PET-CT.
While magnetic resonance imaging (MRI) is a well-established technology with a long history of use, enhanced MRI methods such as diffusion tensor imaging (DTI), diffusion-weighted imaging (DWI), susceptibility-weighted imaging (SWI), and dynamic susceptibility contrast (DSC) imaging technologies are becoming more widely used in North America and Europe.
In terms of quantitative analysis, brain imaging software is a helpful supplement to the scanned pictures produced by these modalities.
Quantitative insights into the anatomy, biomarkers, and other minor irregularities in the brain can help doctors diagnose neurological illnesses more accurately.
Factors such as the rising frequency of neurological illnesses, the developing AI integration in the field of medical imaging, and the increasing need for safer and non-invasive medical imaging technologies are driving the market for brain disease modalities and software.
According to BIS Research, the global brain disease modalities and software market was valued at $13.05 billion in 2021 and is predicted to reach $21.86 billion by the end of 2031. During the forecast period from 2022 to 2031, the market is estimated to grow at a CAGR of 5.31%.
What is Positron Emission Tomography (PET)?
PET stands for positron emission tomography, which is a nuclear medicine process that evaluates the metabolic activity of cells in bodily tissues. PET is a type of imaging that combines nuclear medicine and biochemistry.
PET is mostly used in individuals with brain or heart disorders, as well as cancer, to observe biochemical changes in the body, such as the heart muscle’s metabolism (the process by which cells convert food into energy after it is digested and absorbed into the circulation).
PET varies from those other nuclear medicine exams as it identifies metabolism within biological tissues, whereas other nuclear medicine exams measure the quantity of a radioactive chemical gathered in a specific region to assess the tissue’s function.
PET operations were originally conducted in specialized PET facilities since the equipment needed to generate the radiopharmaceuticals, such as a cyclotron and a radiochemistry lab, as well as the PET scanner, had to be accessible.
Now, radiopharmaceuticals are manufactured in a variety of locations and delivered to PET facilities, requiring just the scanner to complete a PET scan.
PET-Computed Tomography (CT) Scans
PET scans are a sort of diagnostic technology that can be used to diagnose and treat cancer. It’s feasible to use it in conjunction with a CT scan. A PET-CT scan is what physicians call it if this is the case. It is, however, sometimes alluded to as a PET scan.
In some malignancies, PET-CT scanning can assist in identifying cancer and estimating its stage. The term “stage” refers to the location of cancer and whether it has spread.
Doctors will also discover the stage of cancer and how it is impacting your body’s processes. Knowing what stage of cancer you have might help you and your physician decide on the best treatment option. It can also help your healthcare provider forecast overall condition.
Are PET-CT scans safe?
During PET-CT scans, there is a risk of exposure to radiation. This sort of scan employs X-Rays, the material utilized in the PET scan, or a combination of the two. Less radiation is emitted when examining a smaller body region. A CT scan alone without dye that aids in the visualization of details gives the same result.
The advantages of these testing generally outweigh the hazards. Individuals will be exposed to minor levels of radiation throughout these examinations. There has been no evidence that this tiny dosage of radiation causes damage.
There could be a small, elevated risk in the future for children or other persons that require numerous PET scans, CT scans, and X-Rays. Doctors can utilize lower-dose scans or restrict the number of locations that must be examined.
PET–Magnetic Resonance Imaging (MRI)
PET–MRI is a hybrid imaging technique that combines MRI soft tissue morphological imaging and PET functional imaging.
Oncology, cardiology, neurology, and neuroscience are the primary clinical domains of PET-MRI at the moment. At present, studies are being undertaken to better understand the benefits of the novel PET-MRI diagnostic approach.
The method combines MRI’s excellent structural and functional characterization of tissue with PET imaging’s exceptional sensitivity and tracking of individually labeled cell types or cell receptors.
Clinical and pre-clinical combined PET-MR systems are available from several firms; clinical systems are supplied from Philips, Siemens, and GE.
The merging of the two techniques is approached in a variety of ways. Some designs are simply different machines in the same room with a bed that allows a patient to be transferred from one scanner to another.
Fully integrated systems are the most difficult to implement technically, but they offer the largest benefits in terms of the capacity to conduct simultaneous, with perfectly aligned acquisitions.
The need for neuroimaging services decreased but was offset by the need for pulmonary imaging and COVID-19 therapy tests.
As a result, most hospitals have redirected funds to store the tools needed to combat COVID-19, which appears to be more critical.
PET, PET-CT, and PET-MRI imaging modalities are likely to have a higher part of the worldwide brain illness modalities and software market in the future.
Imaging methods that integrate the capabilities of many modalities, such as PET and MRI, are likely to help in more precise diagnosis.
Curious about which innovative technology is gaining traction in your industry? BIS Research provides the most up-to-date market research and studies. Connect with us at email@example.com to learn more.